CN114401742B - 通过转换疗法治疗rms - Google Patents

通过转换疗法治疗rms Download PDF

Info

Publication number
CN114401742B
CN114401742B CN202080064158.9A CN202080064158A CN114401742B CN 114401742 B CN114401742 B CN 114401742B CN 202080064158 A CN202080064158 A CN 202080064158A CN 114401742 B CN114401742 B CN 114401742B
Authority
CN
China
Prior art keywords
ofatuzumab
administered
disease
treatment
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080064158.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN114401742A (zh
Inventor
K·拉马纳坦
D·A·赫林
M·巴格
M·梅尔施海姆克
M·齐恩
R·平吉力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72709332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN114401742(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN202410529206.7A priority Critical patent/CN118436777A/zh
Priority to CN202410529209.0A priority patent/CN118403156A/zh
Publication of CN114401742A publication Critical patent/CN114401742A/zh
Application granted granted Critical
Publication of CN114401742B publication Critical patent/CN114401742B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080064158.9A 2019-09-11 2020-09-10 通过转换疗法治疗rms Active CN114401742B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410529206.7A CN118436777A (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms
CN202410529209.0A CN118403156A (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19196789 2019-09-11
EP19196789.2 2019-09-11
EP20154736.1 2020-01-30
EP20154736 2020-01-30
PCT/EP2020/075332 WO2021048280A1 (en) 2019-09-11 2020-09-10 Treatment of rms by switching therapy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410529209.0A Division CN118403156A (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms
CN202410529206.7A Division CN118436777A (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms

Publications (2)

Publication Number Publication Date
CN114401742A CN114401742A (zh) 2022-04-26
CN114401742B true CN114401742B (zh) 2024-05-24

Family

ID=72709332

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080064158.9A Active CN114401742B (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms
CN202410529206.7A Pending CN118436777A (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms
CN202410529209.0A Pending CN118403156A (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410529206.7A Pending CN118436777A (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms
CN202410529209.0A Pending CN118403156A (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms

Country Status (15)

Country Link
US (1) US20220298253A1 (enExample)
EP (2) EP4230655A3 (enExample)
JP (2) JP7794735B2 (enExample)
KR (1) KR20220062025A (enExample)
CN (3) CN114401742B (enExample)
AU (1) AU2020344154A1 (enExample)
CA (1) CA3150947A1 (enExample)
DK (1) DK3864053T3 (enExample)
ES (1) ES2957112T3 (enExample)
FI (1) FI3864053T3 (enExample)
IL (1) IL290619A (enExample)
LT (1) LT3864053T (enExample)
MX (1) MX2022003010A (enExample)
SI (1) SI3864053T1 (enExample)
WO (1) WO2021048280A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
EP4707302A2 (en) * 2020-04-09 2026-03-11 Novartis AG Ofatumumab for treating ms while maintaining serum igg
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684553A (zh) * 2012-08-03 2015-06-03 前进制药公司 治疗多发性硬化症的组合疗法
CN106573014A (zh) * 2014-04-29 2017-04-19 梯瓦制药工业有限公司 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德
CN109641965A (zh) * 2016-08-15 2019-04-16 诺华股份有限公司 使用奥法木单抗治疗多发性硬化的方案和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684553A (zh) * 2012-08-03 2015-06-03 前进制药公司 治疗多发性硬化症的组合疗法
CN106573014A (zh) * 2014-04-29 2017-04-19 梯瓦制药工业有限公司 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德
CN109641965A (zh) * 2016-08-15 2019-04-16 诺华股份有限公司 使用奥法木单抗治疗多发性硬化的方案和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMIT BAR-OR ET AL."Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study".NEUROLOGY.2018,第90卷(第20期),e1805-e1814. *
L KAPPOS ET AL."Ofatumumab versus teriflunomide in relapsing multiple sclerosis:baseline characteristics of two pivota phase 3 trials （ASCLEPIOS land ASCLEPIOS =I) P965".MULTIPLE SCLEROSIS JOURNAL.2018,第24卷(第2期),526-527. *
Novartis."A randomized,double-blind, ouble-dummy parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis".Clinical Trial Protocol.2018,1-86. *

Also Published As

Publication number Publication date
MX2022003010A (es) 2022-06-02
CN118403156A (zh) 2024-07-30
LT3864053T (lt) 2023-09-11
JP7794735B2 (ja) 2026-01-06
ES2957112T3 (es) 2024-01-11
WO2021048280A1 (en) 2021-03-18
JP2026016387A (ja) 2026-02-03
EP3864053B1 (en) 2023-07-05
IL290619A (en) 2022-04-01
CN114401742A (zh) 2022-04-26
FI3864053T3 (fi) 2023-09-13
EP4230655A2 (en) 2023-08-23
KR20220062025A (ko) 2022-05-13
US20220298253A1 (en) 2022-09-22
CN118436777A (zh) 2024-08-06
EP4230655A3 (en) 2023-11-01
CA3150947A1 (en) 2021-03-18
EP3864053A1 (en) 2021-08-18
AU2020344154A1 (en) 2022-04-07
JP2022548575A (ja) 2022-11-21
SI3864053T1 (sl) 2023-12-29
DK3864053T3 (da) 2023-09-11

Similar Documents

Publication Publication Date Title
CN114401742B (zh) 通过转换疗法治疗rms
JP2024156984A (ja) 難治性全身型重症筋無力症の処置のための方法
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
Kes et al. Recommendations for diagnosis and management of multiple sclerosis
WO2023144699A1 (en) Methods for treatment of subjects with plaque psoriasis of the scalp
CA3229704A1 (en) Ofatumumab for treating pediatric ms
JP2026009900A (ja) 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ
RU2849464C1 (ru) Лечение rms путем смены терапии
Ryan et al. Providing pharmaceutical care to the multiple sclerosis patient
HK40051003A (en) Treatment of rms by switching therapy
HK40051003B (en) Treatment of rms by switching therapy
Saeidi et al. Observational Study on the Safety and Efficacy of Rituximab in Multiple Sclerosis: Insights from North-Eastern Iran: Rituximab Efficacy and Safety in MS: Iran
CN117813328A (zh) 用于治疗儿童ms的奥法妥木单抗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant